DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Heinz body anemia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHeinz body anemia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for heinz body anemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
hemoglobin subunit beta (HBB) — HBB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1DXT · 1.7 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
The 1970 report identifies Hb-Bristol (β67 Val→Asp) as the cause of haemolytic anaemia in the original patient with idiopathic Heinz body anaemia. The unstable haemoglobin constituted 36% of total haemoglobin and had low oxygen affinity, which the authors state accounts for the patient’s normal development despite permanent severe anaemia. Synthesis rates of β Bristol and β A chains were identical, so the reduced amount of Hb-Bristol in the haemolysate was attributed to precipitation of the abnormal protein. The haemoglobin could not be separated by electrophoresis because the abnormal aspartic acid interacts with the adjacent histidine at β63.
Two cases from 1981 describe Heinz body haemolytic anaemia after protracted sniffing of amyl nitrite and butyl nitrite. Nitrites are powerful oxidising agents that cause haemoglobin to be oxidised to methaemoglobin. One patient developed symptomatic anaemia and splenomegaly. Other possible causes of Heinz body formation were excluded by appropriate tests.
A 1989 study of Hb Warsaw (β42 Phe → Val) found four affected members in two generations of a Polish-American family with congenital Heinz-body haemolytic anaemia and cyanosis. Two of the four developed severe pulmonary hypertension, one fatally. Affected blood showed decreased oxygen affinity and elevated methaemoglobin levels. The unstable haemoglobin fraction precipitated rapidly after exposure to isopropyl alcohol or heat. The amino acid substitution is at the same position as Hb Hammersmith and Hb Bucuresti-Louisville.
A 2017 safety and immunogenicity study of subcutaneous HX575 epoetin alfa in 416 patients with chronic kidney disease reported that binding anti-erythropoietin antibodies were detected in 7 patients (1.7%), none of whom developed neutralising antibodies. Four of the 7 later tested negative while continuing treatment. Three had low antibody titres at the last assessment. No clinical signs of immunogenicity or hypersensitivity were observed. The study was not designed for Heinz body anaemia and provides no data on that condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Haematology · 1970 · 79 citations
Idiopathic Heinz Body Anaemia: Hb‐Bristol (β67 (E11) Val→Asp)
AbstractS ummary . It is shown that the haemolytic anaemia in the original patient with ‘idiopathic Heinz body anaemia’ is due to the presence of 36% unstable haemoglobin: Hb‐Bristol (β67 (E11) Val→Asp). This haemoglobin has a low oxygen affinity which accounts for the normal development of this patient in spite of the presence of permanent severe anaemia. The relative rates of synthesis of β Bristol ‐ to β A ‐chains were identical, indicating that the reduced amount of Hb‐Bristol found in the haemolysate is due to precipitation of the abnormal protein. The inability to separate this haemoglobin by electrophoresis is due to interaction of the abnormal aspartic acid with the adjacent histidine at β63 (E7).
The Medical Journal of Australia · 1981 · 33 citations
HEINZ BODY HAEMOLYTIC ANAEMIA AFTER SNIFFING VOLATILE NITRITES
AbstractTwo cases are reported of Heinz body haemolytic anaemia after the sniffing of amyl nitrite and butyl nitrite for protracted periods. Nitrites are powerful oxidizing agents which are recognized to cause haemoglobin to be oxidized to methaemoglobin. One patient developed a symptomatic anaemia and also splenomegaly. Other possible causes of Heinz body formation were ruled out by the appropriate tests.
American Journal of Hematology · 1989 · 22 citations
Hb Warsaw (β42 Phe → Val): An unstable hemoglobin with decreased oxygen affinity. I. Hematologic and clinical expression
AbstractFour members in two generations of a Polish-American family exhibited findings of congenital Heinz-body hemolytic anemia accompanied by cyanosis. Two of the affected family members have also developed severe pulmonary hypertension, with a fatal outcome in one of them. Blood from the affected individuals showed decreased oxygen affinity and contained elevated levels of methemoglobin. An unstable hemoglobin fraction underwent rapid precipitation following exposure of the red cell lysates to isopropyl alcohol or heat. This hemoglobin contained a newly identified abnormal beta chain with an amino acid substitution at the same position as that of Hb Hammersmith and Hb Bucuresti-Louisville.
Clinical Nephrology · 2017 · 10 citations · open access
Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients
AbstractAIM: To assess the safety and immunogenicity of subcutaneous (SC) HX575 (epoetin-α) in dialysis- and nondialysis-dependent adult patients with chronic kidney disease (CKD). METHODS: Open-label, single-arm, multicenter study in patients (n = 416) from Germany, Italy, Poland, Romania, Russia, Turkey, and Ukraine. RESULTS: Mean (standard deviation (SD)) age was 52.3 (15.8) years, all patients were Caucasian, and similar proportions were male/female. 250 patients (60.1%) were erythropoiesis-stimulating agent (ESA)-naïve, and 166 (39.9%) were receiving ESA maintenance therapy at study start; mean (SD) on-study treatment duration with HX575 was 43.4 (15.8) weeks and 45.3 (13.7) weeks, respectively. Binding antierythropoietin (EPO) antibodies were detected by radioimmunoprecipitation (RIP) assay in 7 patients (1.7%; incidence 0.019); 5 of these were ESA-naïve at study entry. No patient developed neutralizing antibodies as determined in a cell-based epoetin neutralizing assay. Of the 7 patients with a positive binding anti-EPO RIP assay, 4 tested negative at later time points while continuing HX575 treatment. Three patients had low titers of anti-EPO antibodies at the last study assessment. There were no clinical signs of immunogenicity or hypersensitivity. CONCLUSIONS: SC HX575 was effective for correcting and maintaining correction of anemia, and the mean weekly dose remained stable over time. .
Frontiers in Veterinary Science · 2023 · 6 citations · open access
Case series: Heinz body formation in 13 multimorbid dogs following metamizole administration
AbstractBackground: Heinz Body (HB) anemia is a result of oxidative damage and is an uncommon condition in dogs relative to cats. In this retrospective case series, clinical features, laboratory values, concurrent diseases, and outcomes of 13 multimorbid dogs that developed HBs after receiving metamizole are reported. Case description: Of the 13 dogs in this case series that developed HBs, 10 were older and multimorbid, but the only feature that all the dogs had in common was receiving metamizole. HBs were detected in 7 out of 13 dogs within a few days (3-10 days) after starting metamizole treatment. The metamizole dose was 38-159 mg/kg/day. The highest percentage of HBs detected was 28-95% (mean, 46%). There was no correlation between the percentage of HBs and the daily dose of metamizole. All but 1 dog had mild-to-severe anemia at the time of the highest HB appearance. The number of HBs did not correlate with the hematocrit at that time. In 8/12 dogs, no stress leukogram was present. Approximately half of the dogs with HBs also had evidence of gastrointestinal hemorrhage, which could have masked additional oxidative damage. Conclusion: In multimorbid dogs that develop regenerative anemia after receiving metamizole, hemolysis due to HB development caused by oxidative damage should be considered as an important differential diagnosis.
AbstractThis book is based on the American College of Physicians' course in hematology for internists given at the University of Rochester. The book is somewhat disjointed because of the numerous contributors, 26 in all. The text is divided into four parts, dealing respectively with anemias, problems of hemostasis, myeloproliferative disorders, and disorders of the lymphatic system. In the section on anemias, there is no chapter on iron-deficiency anemia which is certainly the most common type of anemia and probably the most common disorder in the world. Yet there is a 15-page chapter on Heinzbody disorders, and a ten-page chapter on sideroblastic anemias, both relatively uncommon conditions. There is no section in the book on blood banking or irnmunohematology, although the brief chapter on transfusion therapy is very useful. Nor is there any section devoted to infectious mononucleosis. Although the chapter on diffuse intravascular coagulation is a little skimpy, the section
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
